Table 2.
Summary of time to event outcomes of patients expressing different BCR-ABL transcripts (e13a2, e14a2, and coexpressed e13a2 and e14a2) according to optimal ELN responses achieved at the 3- and 6-month landmark: EFS, TFS, and OS
| % 5-year outcome EFS/TFS/OS | ||||
|---|---|---|---|---|
| e13a2 | e14a2 | Both | ||
| Cytogenetic response* | ||||
| 3 months | MCyR | 83/90/90 | 90/94/95 | 91/99/97 |
| No MCyR | 54/78/85 | 61/90/91 | 61/100/100† | |
| 6 months | CCyR | 88/91/93 | 94/96/97 | 94/100/99 |
| No CCyR | 50/77/80 | 65/84/93 | 63/100/100† | |
| Molecular response‡ | ||||
| 3 months | ≤10% | 82/89/91 | 90/95/96 | 87/99/97 |
| >10%§ | −/−/100 | −/−/− | −/−/− | |
| 6 months | <1% | 89/92/94 | 94/96/97 | 94/100/98 |
| ≥1% | 55/71/79 | 43/91/89 | 30/100/100 | |
*
Optimal ELN response by cytogenetic response: major cytogenetic response at 3 months or complete cytogenetic response at 6 months.
†
n = 11 for coexpressed transcripts with no MCyR at 3 months and n = 14 with no MCyR at 6 months.
‡
Optimal ELN response by molecular response: BCR-ABL1 ≤10% at 3 months or <1% at 6 months.
§
Less than 5 patients in this group.